| News Updates |
 |
GSK enters agreement with U.S. government to lower drug prices and expand access to ...
ViiV Healthcare | December 19, 2025
|
 |
[Press release] MHRA approves lenacapavir for the prevention of sexually transmitted HIV-1 infection
European AIDS Treatment Group | December 19, 2025
|
 |
Subcutaneous Lenacapavir in People with Multidrug-Resistant HIV-1: 156 Week Results of ...
Oxford Academic | December 19, 2025
|
 |
FDA approves first new antibiotics to treat gonorrhea in decades, with hope to combat drug resistance
CNN | December 12, 2025
|
 |
IDWeek 2025: Real-world findings show lenacapavir effective in highly treatment-experienced people with HIV
EATG | December 6, 2025
|
 |
Common water pill may help HIV medicines work faster and reduce inflammation
EATG | December 3, 2025
|
 |
Long-term HIV control: Could this combination therapy be the key?
EATG | December 3, 2025
|
 |
Merck's oral HIV treatment as effective as Gilead's Biktarv
The Jerusalem Post | November 24, 2025
|
 |
Systemic inflammation in suppressed HIV similar after switch to 3-drug ART
EATG | November 22, 2025
|
 |
Systemic Inflammation in Suppressed HIV Similar After Switch to 3-Drug ART
IDA | November 21, 2025
|
 |
Merck's oral HIV treatment meets main goal in late-stage study
Reuters | November 19, 2025
|
 |
Antibody drugs show promise for treating bird flu and HIV
Nature | November 5, 2025
|
 |
CVS Caremark tells AIDS activists Gilead needs to lower the price of its new HIV drug to get on formularies
HIV+HEP | October 22, 2025
|
 |
HIV Preventive Treatment Could Be Sold for One Thousandth of Current List Price
IDSA | October 19, 2025
|
 |
Gilead to present data on potential first weekly oral treatment for HIV
Yahoo! News | October 15, 2025
|
 |
Once-Weekly Oral ISL/LEN Combo for HIV Treatment Found Safe and Effective, With High Adherence
Infectious Disease Special Edition | October 17, 2025
|
 |
ViiV Healthcare announces 96-week data reaffirming Dovato is as effective as Biktarvy in maintaining virological suppression of HIV-1 with...
ViiV Healthcare | October 17, 2025
|
 |
Novel HIV Combo Therapy of Lenacapavir and 2 bNAbs Found Effective, Well Tolerated in in Phase 2 Trial
Infectious Disease Special Edition | October 17, 2025
|
 |
Integrase inhibitors maintain efficacy despite “outside” mutations, UK study finds
European AIDS Treatment Group | October 12, 2025
|
 |
'We can end HIV': Groundbreaking preventative drug to be rolled out for $40 a year from 2027
France24 | September 25, 2025
|
 |
Gates Foundation partners with Indian manufacturer to drive down cost of, accelerate access to groundbreaking HIV prevention tool
Gates Foundation | September 24, 2025
|
 |
UNAIDS welcomes the announcement of new deals to make new HIV prevention medicines available and affordable for people in need
UNAIDS | September 24, 2025
|
 |
HIV Drug Resistance Is Declining Over Time
POZ Magazine | September 24, 2025
|
 |
From Bench to Breakthrough: How Curiosity Led to an Extraordinarily Effective HIV Drug
University of Utah Health | September 22, 2025
|
 |
New oral antiretroviral shows potential as long-acting HIV pre-exposure prophylaxis
News Medical | August 26, 2025
|
 |
European Commission Authorizes Twice-Yearly Yeytuo® (Lenacapavir) for HIV Prevention
Gilead | August 26, 2025
|
 |
HIV: Monthly PrEP Drug Candidate Shows Promise
Newsweek | August 26, 2025
|
 |
HIV Treatment Overview
NIH | August 20, 2025
|
 |
Lenacapavir will not end the HIV epidemic in the current US political climate
The Lancet | August 2025
|
 |
Innovative administration of long-acting injectables for HIV treatment enhancement at home (INVITE-HOME): implementation science...
NIH | August 5, 2025
|
| |
|